New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
US $ 555,000 invested by Wavemaker Partners in pre-seed round
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
The companies plan to use the proceeds to retire debt and expand operations
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Recall does not include any metabolic deficiency nutrition formulas
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Evonik invests in start-up to improve patient recovery after open-chest surgery
Subscribe To Our Newsletter & Stay Updated
